ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO693

Suppression of Thyroid Profile During Roxadustat Treatment in CKD Patients

Session Information

  • Anemia and Iron Metabolism
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Cheng, Yuan, 1Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, P.R. China, Shenzhen, China
  • Xiang, Qiong, 1Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, P.R. China, Shenzhen, China
  • Cao, Tao, 1Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, P.R. China, Shenzhen, China
  • Tang, Fei, 1Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, P.R. China, Shenzhen, China
  • Wan, Qijun, 1Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, P.R. China, Shenzhen, China
Background

Roxadustat has been used for renal anemia. To date, roxadustat induced suppression of thyrotropin secretion have been only described in two cases reports, but more data from a larger cohor are needed.

Methods

A total of 151 patients with renal anemia were collected in this retrospective cohort study. Changes in thyroid hormone and TSH were evaluated before and during the use of roxadustat or erythropoietin.

Results

FT3, FT4, T3, T4 and TSH level were lower during the use of roxadustat compared to baseline compared to erythropoietin group. 48.68% of patients had TSH levels dropped by more than 50%. By multivariate analysis, treatment of roxadustat was independently associated with the lower of TSH level by 41.30% (P<0.001).

Conclusion

This corhort study first finds that the suppression of thyroid profile is commonly related in CKD patients used roxadustat.

Multivariate regression
 UnadjustedModel 1Model 2
 β (95% CI)Pβ (95% CI)Pβ (95% CI)P
Erythropoietinreference reference reference 
Roxadustat      
Percent change of T3, %-22.62 (-35.58, -9.66)0.001-21.85 (-35.48, -8.22)0.003-14.92 (-31.61, -1.77)0.086
Percent change of T4, %-30.94 (-43.77, -18.12)<0.001-27.05 (-39.87, -14.22)<0.001-21.87 (-38.15, -5.59)<0.001
Percent change of FT3, %-19.19 (-28.81, -9.58)<0.001-20.13 (-29.85, -10.40)<0.001-18.75 (-30.77, -6.73)<0.001
Percent change of FT4, %-9.48 (-14.24, -4.73)<0.001-9.93 (-14.74, -5.13)<0.001-9.32 (-15.26, -3.39)<0.001
Percent change of TSH, %-35.77 (-50.95, -20.58)<0.001-34.32 (-49.69, -18.95)<0.001-41.30 (-59.76, -22.83)<0.001

Model 1 is adjusted for sex, age, BMI, DM and hypertension. Model 2 is adjusted for variables in Model 1 and, CRP, serum albumin, uric acid, total cholesterol and transferrin saturation.

TSH change

TSH decline >50%

Funding

  • Government Support – Non-U.S.